He
joined Schering-Plough in 1993 as executive vice president of discovery
research. Such statements are subject to certain factors, risks and uncertainties
that may cause actual results, events and performances to differ materially
from those referred to in such statements.

mammal genetics

, Pickett earned
his Ph. Through internal research
and collaborations with partners, Schering-Plough discovers, develops ,
manufactures and markets advanced drug therapies to meet important medical
needs. These risks include statements
which address operating performance, events or developments that we expect or
anticipate will occur in the future, such as projections about our future
results of operations or our financial condition, benefits from the alliance
with Boston Scientific, research, development and commercialization of our
product candidates, and in particular whether early-stage clinical trial
results are any indication of results in subsequent clinical trials,
anticipated trends in our business, manufacture of sufficient and acceptable
quantities of our proposed products, approval of our product candidates,
meeting additional capital requirements, benefits from listing on the Nasdaq
Stock Market, and other risks that could cause actual results to differ
materially.

mammal proposals

Black Engineer +
Information Technology magazine as one of the "50 Most Important Blacks in
Technology .

jesse medics

Pickett has been widely published in leading scientific journals and has
been a frequent speaker at major scientific conferences and symposia.corautus. For more
information, please visit http://www.

genetics trials

Head of Schering-Plough Research Institute Named to New Jersey High-Tech Hall of Fame

Schering-Plough's vision is to earn the trust of the physicians,
patients and customers served by its more than 30,000 people around the world.M. Eastern time on August 11.'s Securities
and Exchange Commission filings, including, but not limited to, the risk
factors in Corautus' 2004 Annual Report on Form 10-K filed on March 22, 2005,
which are incorporated by reference into this press release .

nih genetics

About Corautus Genetics
Corautus Genetics Inc. is a clinical-stage biopharmaceutical company
dedicated to the development of gene transfer therapy products for the
treatment of cardiovascular (severe angina) and peripheral vascular disease.

recombinant mammal

, senior
vice president, Schering-Plough Corporation (NYSE: SGP), and president,
Schering-Plough Research Institute, was chosen by the HealthCare Institute of
New Jersey (HINJ) as its pharmaceutical/medical technology research nominee
for the New Jersey High-Tech Hall of Fame., locations.

This category is for companies, organizations, research institutes and investigators who are involved in clinical trials of gene therapy products.

duchenne advises

D. Domestic callers can access the replay by dialing
(888) 286-8010, and international callers can access the replay by dialing
(617) 801-6888; the PIN access number is 53844835.

proposals dystrophy

A graduate of California State University, Hayward, Calif.com.

recombinant nih

KENILWORTH, N. The event honors leaders in government, business ,
research and education who have contributed significantly to the growth and
prosperity of the biotechnology, high technology and pharmaceutical
industries. He currently serves as a member of The
National Academies Committee on Science, Engineering and Public Policy and The
Institute of Medicine's Forum on Drug Discovery, Development and Translation. in cell biology from the University of California, Los Angeles
(UCLA).

cystic medics

Food
and Drug Administration (FDA) Science Board, the Advisory Committee to the
Director of the National Institutes of Health and The National Cancer Policy
Board of the Institute of Medicine.schering-plough.

Richard Otto,
President and Chief Executive Officer of Corautus, will host the call.

proposals nih

medics ethical

, Cecil B. Pickett, Ph. He held various positions of
increasing responsibility during his 15-year tenure at Merck in the company's
Rahway, NJ, Montreal, Canada, and West Point, Pa.

trials ethical

jesse recombinant

The award honors innovators in
life science and high technology industries.

Previously, Pickett served as senior vice president, basic
research, at Merck Research Laboratories ., and its Web site is
http://www. ATLANTA, Corautus Genetics Inc. In July 2003, Corautus entered into a
strategic alliance with Boston Scientific Corporation (NYSE: BSX) to develop,
commercialize and distribute the VEGF-2 gene therapy products.com.

hurdles merits

J. Alternatively,
domestic callers may participate in the conference call by dialing
(866) 770-7146, and international callers may participate in the conference
call by dialing (617) 213-8068. Webcast and telephone replays of the
conference call will be available approximately two hours after the completion
of the call. These risks are discussed in Corautus Genetics Inc.

trials recombinant

Among
his many professional activities, he has served as a member of the U.
Corautus is currently developing and testing a gene transfer product using the
Vascular Endothelial Growth Factor-2 (VEGF-2) gene to promote therapeutic
angiogenesis in ischemic muscle.corautus.

plasmid mammal

J."
A member of the Schering-Plough Executive Management Team (EMT), Pickett
is responsible for the planning, management and oversight of Schering-Plough's
research and development programs across all therapeutic categories.J.

gene eukaryotic

S.
The company is based in Kenilworth, N.

merits acceptability

Schering-Plough is a global science-based health care company with leading
prescription, consumer and animal health products. (Nasdaq: VEGF), a
biopharmaceutical company dedicated to the development of innovative gene
transfer therapy products for the treatment of cardiovascular (severe angina)
and peripheral vascular disease, will release its second quarter 2005
financial results on Thursday , August 11, 2005.

acceptability proposals

Forward-Looking Statement
This press release may contain forward -looking statements made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.

therapy merits

Corautus Genetics Inc. to Host Conference Call on August 11 2005

To access the live webcast, please log on to the Company's website at
http://www.

eukaryotic trials

The Induction Dinner is cosponsored by HINJ, an association of global
pharmaceutical and medical technology companies in New Jersey; the
Biotechnology Council of New Jersey; and AeA, Advancing the Business of
Technology , a nationwide trade association that represents all segments of the
technology industry.

plasmid acceptability

Pickett was recently named to Black Enterprise magazine's list of the
"75 Most Powerful Blacks in Corporate America" and by U.
He is also an elected member of the Institute of Medicine of the National
Academy of Science. The Company will also webcast
a conference call to discuss the results and progress of its therapeutic
development program at 11:00 A.

nih merits

This year's dinner will take place on Thursday, April 21, 2005,
at the Woodbridge Hilton in Iselin, N.S.com and go to the Investor Relations section .